FACULTY

Joaquim Bellmunt, MD, PhD
Director, Bladder Cancer Center
David Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, MA

Julie Brahmer, MD
Institute Director
Professor of Oncology
Sloan Kettering Comprehensive Cancer Center
Johns Hopkins School of Medicine
Baltimore, MD

Drew M. Pardoll, MD, PhD
Asst. Professor of Oncology
Co-director, Biological Therapy and Cancer Immunology Program
Sloan Kettering Institute for Cancer Immunology
Baltimore, MD

Ezra Cohen, MD, FRCPSC, FASCO
Professor, Division of Hematology/Oncology
Department of Medicine
University of British Columbia
Veterans Affairs Medical Center, Vancouver
Vancouver, BC

Elaine R. Mardis, PhD
National Foundation Endowed Chair in Genome Medicine
The Ohio State University College of Medicine
Columbus, OH

Michael A. Postow, MD
Associate Professor of Pediatrics
Memorial Sloan Kettering Cancer Center
New York, NY

Joaquim Bellmunt, MD
Director, Cancer Immunology Program
Cancer Immunotherapy Program
Massachusetts General Hospital
Boston, MA

Laura and Isaac Perlmutter Cancer Center
Deputy Director
Memorial Sloan Kettering Cancer Center
New York, NY

Jeffrey S. Weber, MD, PhD
Division of Hematology/Oncology
Measure, the Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, MD

David F. McDermott, MD
Division of Medical Oncology
The Sidney Kettering Comprehensive Cancer Center
New York, NY

Drew M. Pardoll, MD, PhD
Associate Professor of Oncology
Sloan Kettering Institute for Cancer Immunology
Baltimore, MD

Elaine R. Mardis, PhD
National Foundation Endowed Chair in Genome Medicine
The Ohio State University College of Medicine
Columbus, OH

Marcelo V. Maus, MD, PhD
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Laura and Isaac Perlmutter Cancer Center
Deputy Director
Memorial Sloan Kettering Cancer Center
New York, NY

Ezra Cohen, MD, FRCPSC, FASCO
Professor, Division of Hematology/Oncology
Department of Medicine
University of British Columbia
Veterans Affairs Medical Center, Vancouver
Vancouver, BC

Elaine R. Mardis, PhD
National Foundation Endowed Chair in Genome Medicine
The Ohio State University College of Medicine
Columbus, OH

Marcelo V. Maus, MD, PhD
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Registration Fees

<table>
<thead>
<tr>
<th></th>
<th>Advanced</th>
<th>On-Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>$129</td>
<td>$149</td>
</tr>
<tr>
<td>Fellows*</td>
<td>$99</td>
<td>$119</td>
</tr>
<tr>
<td>Nurses, PAs, Other Health Care Professionals</td>
<td>$99</td>
<td>$119</td>
</tr>
</tbody>
</table>

Industry**

$339 $369

*Accreditation may only be awarded to participants who meet course criteria for the duration of the activity.
**MD/DO license required.
For registration assistance, please call (888) 949-0045 or email info@go-per.com.

TWO WAYS TO REGISTER

Online
gotoper.com/go/ICICI18TRI

Or

Call
1-609-378-3701
Overview

The 3rd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application is an exciting and fast-paced Congress that will provide a multi-module curriculum-based program focusing exclusively on immunotherapies and their application to the management of cancer. This intensive, 1-day interactive program will bring you a comprehensive review of the key data sets that are most relevant to the application of these novel strategies for you who manage some of the most difficult-to-treat forms of cancer.

What You Will Learn at This Year’s Meeting!

• Pan-tumor immunotherapies are moving from the bench to the bedside
• The mechanistic rationale for the application of immunotherapies to target specific tumors
• The use of biomarkers to allow personalized care for your patients
• Genomic-based personalized immunotherapy and less invasive approaches to biopsy
• Immunotherapies can be sequenced or layered with other agents to optimize outcomes

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am</td>
<td>Registration and Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00 am</td>
<td>Welcome, Introductions, Pre-Session Survey</td>
<td>Antoni Ribas, MD, PhD</td>
</tr>
<tr>
<td>8:15 am</td>
<td>Biology of Immunotherapy</td>
<td></td>
</tr>
<tr>
<td>8:35 am</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>8:40 am</td>
<td>Ongoing Research in Biomarkers for Immunotherapy</td>
<td></td>
</tr>
<tr>
<td>9:00 am</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>9:05 am</td>
<td>Targeting PD1 clinical applications - molecular basis of PD1 response - microsatellite instability</td>
<td>Nayer A. Rizvi, MD</td>
</tr>
<tr>
<td>9:25 am</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>9:30 am</td>
<td>New Approaches in Immunotherapy</td>
<td>Antoni Ribas, MD, PhD</td>
</tr>
<tr>
<td>9:50 am</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>9:55 am</td>
<td>Morning Break</td>
<td></td>
</tr>
<tr>
<td>10:20 am</td>
<td>Improving the Safety of Immunotherapy: A Practical Guide to Addressing Immune-Related Adverse Events</td>
<td>Michael A. Postow, MD</td>
</tr>
<tr>
<td>11:05 am</td>
<td>Practical Applications for the Clinic</td>
<td></td>
</tr>
<tr>
<td>11:20 am</td>
<td>Genitourinary Malignancies</td>
<td></td>
</tr>
<tr>
<td>11:20 am</td>
<td>Hematologic Malignancies</td>
<td></td>
</tr>
<tr>
<td>11:35 am</td>
<td>CAR T-Cells: Next Frontiers</td>
<td>Marcella Musa, MD, PhD</td>
</tr>
<tr>
<td>12:05 pm</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>12:15 pm</td>
<td>Post-Session Survey</td>
<td></td>
</tr>
<tr>
<td>12:20 pm</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>1:35 pm</td>
<td>Practical Applications for the Clinic (Continued)</td>
<td></td>
</tr>
<tr>
<td>1:40 pm</td>
<td>MEDICAL CROSSFIRE™: Does Radiation Treatment Synergize with Immunotherapy</td>
<td>Jeffrey S. Weber, MD, PhD</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Checkpoint Inhibitors for Patients With Dermatologic Cancers: What’s New for 2018?</td>
<td>Jeffrey S. Weber, MD, PhD</td>
</tr>
<tr>
<td>2:20 pm</td>
<td>Combinations and Settings</td>
<td></td>
</tr>
<tr>
<td>2:40 pm</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>2:45 pm</td>
<td>Afternoon Break</td>
<td></td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Head and Neck Cancer</td>
<td></td>
</tr>
<tr>
<td>3:10 pm</td>
<td>Integration of Immunotherapy into the Treatment of Head and Neck Cancers</td>
<td>Ezra Cohen, MD, FRCPC, FASCO</td>
</tr>
<tr>
<td>3:35 pm</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>3:40 pm</td>
<td>Lung Cancer</td>
<td></td>
</tr>
<tr>
<td>4:05 pm</td>
<td>Medical Crossfire™: Immunotherapy Alone versus Combinations as First-Line Therapy for Patients with PD-L1-Positive NSCLC (TMB V5 PDL1)</td>
<td>Julie Brahmer, MD</td>
</tr>
<tr>
<td>4:45 pm</td>
<td>Closing Remarks and Adjourn</td>
<td>Antoni Ribas, MD, PhD and Nayer A. Rizvi, MD</td>
</tr>
</tbody>
</table>

For more information and to register visit gotoper.com/go/ICIC18TRI